Dan Brounstein Appointed as New CEO of Avivomed
Avivomed, Inc. has made a significant leadership change by announcing Dan Brounstein as its new Chief Executive Officer. This appointment marks a pivotal moment for the company, which aims to advance innovative neuromodulation therapies designed to enhance the quality of life for patients experiencing disrupted sleep cycles.
Importance of the New Leadership
In the medical device sector, strong leadership is essential, especially when addressing pressing health issues. Millions of individuals struggle with interrupted sleep, and existing treatments often fall short of expectations. Dan Brounstein's extensive experience in neuromodulation combined with his proven ability to develop and launch medical therapies positions him as the optimal leader for Avivomed's future endeavors.
Highlights from Brounstein's Background
Before joining Avivomed, Brounstein served as Chief Strategy Officer at Saluda Medical, where he played a crucial role in the groundbreaking Evoke Pivotal Study. His experience includes successfully launching the Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulator aimed at treating chronic pain. His previous roles include Vice President of Marketing and Clinical Operations at Spinal Modulation, where he contributed to the strategy that brought DRG Stimulation to the market, ultimately leading to the acquisition by St. Jude Medical (now Abbott).
Education and Professional Experience
Brounstein brings over 30 years of experience within the medical device industry. He holds a Bachelor of Science in Bioengineering from UC San Diego and an MBA from UC Berkeley's Haas School of Business. With such a robust educational foundation and a wealth of industry experience, he is well-equipped to guide Avivomed towards its goals.
About Avivomed and Its Vision
Avivomed, Inc. is committed to developing next-generation minimally invasive neuromodulation therapies. Their primary focus is on improving quality of life for individuals who suffer from obstructive sleep apnea. The company's base is in Minneapolis, and it operates within the NuXcel innovation ecosystem. Investors supporting Avivomed’s mission include prominent venture partners.
Looking Towards the Future
The leadership transition signifies Avivomed's commitment to expanding its impact in the field of sleep disorders. The Board of Directors, represented by Mudit K. Jain, PhD, has expressed gratitude to outgoing CEO Steve Masson for his dedication and the progress achieved during his tenure. As Brounstein takes over, there is a tangible excitement regarding the innovative path ahead.
Frequently Asked Questions
Who is Dan Brounstein?
Dan Brounstein is the newly appointed CEO of Avivomed, known for his extensive experience in the medical device industry.
What is Avivomed's primary focus?
Avivomed primarily focuses on developing innovative therapies to address obstructive sleep apnea.
What was Dan Brounstein's role before Avivomed?
Before joining Avivomed, he served as Chief Strategy Officer at Saluda Medical.
Where is Avivomed headquartered?
Avivomed is based in Minneapolis.
What educational background does Dan Brounstein have?
He holds a Bachelor of Science in Bioengineering and an MBA from reputed institutions.
